NEW YORK and LONDON, Feb. 6, 2014 (GLOBE NEWSWIRE) -- Celsus Therapeutics Plc (Nasdaq: CLTX ), an emerging growth, development-stage biotech company, announced today that Dr. Gur Roshwalb, Chief Executive Officer of Celsus, will present at the 2014 BIO CEO & Investor Conference on Monday,

American Depository Shares Listed on the NASDAQ Capital Market Under the Trading Symbol "CLTX" NEW YORK and LONDON, Feb. 5, 2014 (GLOBE NEWSWIRE) -- Celsus Therapeutics Plc (Nasdaq: CLTX ), an emerging growth, development-stage biotech company, announced today the closing of its previously

NEW YORK and LONDON, Jan. 30, 2014 (GLOBE NEWSWIRE) -- Celsus Therapeutics Plc (Nasdaq: CLTX ) (formerly OTCQB:CLSXD), an emerging growth, development-stage biotech company, announced today the pricing of its public offering of 1,333,333 American Depository Shares ("ADSs") on the NASDAQ Capital

NEW YORK and LONDON, Oct. 24, 2013 (GLOBE NEWSWIRE) -- Celsus Therapeutics (OTCQB:CLSXY), an emerging growth, development-stage biopharmaceutical company, announces the appointment of Pablo Jimenez, M.D., to the position of Chief Medical Officer. This appointment reflects Celsus' continued growth